首页 > 最新文献

Trends in cancer最新文献

英文 中文
Advisory Board and Contents 咨询委员会和内容
IF 18.4 1区 医学 Q1 ONCOLOGY Pub Date : 2024-07-09 DOI: 10.1016/s2405-8033(24)00124-9
No Abstract
无摘要
{"title":"Advisory Board and Contents","authors":"","doi":"10.1016/s2405-8033(24)00124-9","DOIUrl":"https://doi.org/10.1016/s2405-8033(24)00124-9","url":null,"abstract":"No Abstract","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":null,"pages":null},"PeriodicalIF":18.4,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141577790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Subscription & copyright page 订阅和版权页面
IF 18.4 1区 医学 Q1 ONCOLOGY Pub Date : 2024-07-09 DOI: 10.1016/s2405-8033(24)00127-4
No Abstract
无摘要
{"title":"Subscription & copyright page","authors":"","doi":"10.1016/s2405-8033(24)00127-4","DOIUrl":"https://doi.org/10.1016/s2405-8033(24)00127-4","url":null,"abstract":"No Abstract","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":null,"pages":null},"PeriodicalIF":18.4,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141572587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
COX2-dependent suppression of anticancer immunity. COX2 依赖性抑制抗癌免疫。
IF 14.3 1区 医学 Q1 ONCOLOGY Pub Date : 2024-07-01 Epub Date: 2024-05-30 DOI: 10.1016/j.trecan.2024.05.006
María Cecilia Lira, Lorenzo Galluzzi, Claire Vanpouille-Box

Prostaglandin E2 (PGE2) is well known to promote tumor progression by boosting cancer cell proliferation while inhibiting anticancer immunity. Recent data from Lacher et al. and Morotti et al. demonstrate that one of the mechanisms through which PGE2 suppresses tumor-targeting immune responses involves downregulation of interleukin 2 (IL2) receptors and consequent inhibition of mitochondrial metabolism in T cells.

众所周知,前列腺素 E2(PGE2)可促进癌细胞增殖,同时抑制抗癌免疫,从而促进肿瘤进展。Lacher 等人和 Morotti 等人的最新数据表明,PGE2 抑制肿瘤靶向免疫反应的机制之一是下调白细胞介素 2(IL2)受体,从而抑制 T 细胞的线粒体代谢。
{"title":"COX2-dependent suppression of anticancer immunity.","authors":"María Cecilia Lira, Lorenzo Galluzzi, Claire Vanpouille-Box","doi":"10.1016/j.trecan.2024.05.006","DOIUrl":"10.1016/j.trecan.2024.05.006","url":null,"abstract":"<p><p>Prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) is well known to promote tumor progression by boosting cancer cell proliferation while inhibiting anticancer immunity. Recent data from Lacher et al. and Morotti et al. demonstrate that one of the mechanisms through which PGE<sub>2</sub> suppresses tumor-targeting immune responses involves downregulation of interleukin 2 (IL2) receptors and consequent inhibition of mitochondrial metabolism in T cells.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":null,"pages":null},"PeriodicalIF":14.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11236508/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141184730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A new BRAF inhibitor breaks resistance barriers. 一种新型 BRAF 抑制剂打破了抗药性障碍。
IF 14.3 1区 医学 Q1 ONCOLOGY Pub Date : 2024-07-01 Epub Date: 2024-06-11 DOI: 10.1016/j.trecan.2024.05.009
Morena Scotece, Matthias Drosten

Approved BRAF inhibitors have shown limited clinical benefit due to recurrent disease progression. In a recent Cancer Discovery paper, Yaeger et al. show that a next-generation BRAF inhibitor, PF-07799933, has widespread therapeutic activity in experimental models and patients who were refractory to treatment with approved BRAF inhibitors.

由于疾病复发,已批准的 BRAF 抑制剂临床疗效有限。在最近的一篇《癌症发现》(Cancer Discovery)论文中,Yaeger 等人指出,新一代 BRAF 抑制剂 PF-07799933 在实验模型和对已批准的 BRAF 抑制剂治疗无效的患者中具有广泛的治疗活性。
{"title":"A new BRAF inhibitor breaks resistance barriers.","authors":"Morena Scotece, Matthias Drosten","doi":"10.1016/j.trecan.2024.05.009","DOIUrl":"10.1016/j.trecan.2024.05.009","url":null,"abstract":"<p><p>Approved BRAF inhibitors have shown limited clinical benefit due to recurrent disease progression. In a recent Cancer Discovery paper, Yaeger et al. show that a next-generation BRAF inhibitor, PF-07799933, has widespread therapeutic activity in experimental models and patients who were refractory to treatment with approved BRAF inhibitors.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":null,"pages":null},"PeriodicalIF":14.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141311839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advancements in combining targeted therapy and immunotherapy for colorectal cancer. 结直肠癌靶向治疗与免疫疗法相结合的进展。
IF 14.3 1区 医学 Q1 ONCOLOGY Pub Date : 2024-07-01 Epub Date: 2024-05-31 DOI: 10.1016/j.trecan.2024.05.001
Manisha Singh, Van Karlyle Morris, Irfan N Bandey, David S Hong, Scott Kopetz

Colorectal cancer (CRC) is a prevalent gastrointestinal cancer posing significant clinical challenges. CRC management traditionally involves surgery, often coupled with chemotherapy. However, unresectable or metastatic CRC (mCRC) presents a complex challenge necessitating innovative treatment strategies. Targeted therapies have emerged as the cornerstone of treatment in such cases, with interventions tailored to specific molecular attributes. Concurrently, immunotherapies have revolutionized cancer treatment by harnessing the immune system to combat malignant cells. This review explores the evolving landscape of CRC treatment, focusing on the synergy between immunotherapies and targeted therapies, thereby offering new avenues for enhancing the effectiveness of therapy for CRC.

结肠直肠癌(CRC)是一种常见的胃肠道癌症,给临床带来了巨大挑战。传统的 CRC 治疗包括外科手术,通常还辅以化疗。然而,无法切除或转移的 CRC(mCRC)是一项复杂的挑战,需要创新的治疗策略。靶向疗法已成为此类病例的治疗基石,可针对特定分子属性进行干预。与此同时,免疫疗法通过利用免疫系统对抗恶性细胞,彻底改变了癌症治疗。本综述探讨了 CRC 治疗不断发展的前景,重点关注免疫疗法和靶向疗法之间的协同作用,从而为提高 CRC 治疗的有效性提供新的途径。
{"title":"Advancements in combining targeted therapy and immunotherapy for colorectal cancer.","authors":"Manisha Singh, Van Karlyle Morris, Irfan N Bandey, David S Hong, Scott Kopetz","doi":"10.1016/j.trecan.2024.05.001","DOIUrl":"10.1016/j.trecan.2024.05.001","url":null,"abstract":"<p><p>Colorectal cancer (CRC) is a prevalent gastrointestinal cancer posing significant clinical challenges. CRC management traditionally involves surgery, often coupled with chemotherapy. However, unresectable or metastatic CRC (mCRC) presents a complex challenge necessitating innovative treatment strategies. Targeted therapies have emerged as the cornerstone of treatment in such cases, with interventions tailored to specific molecular attributes. Concurrently, immunotherapies have revolutionized cancer treatment by harnessing the immune system to combat malignant cells. This review explores the evolving landscape of CRC treatment, focusing on the synergy between immunotherapies and targeted therapies, thereby offering new avenues for enhancing the effectiveness of therapy for CRC.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":null,"pages":null},"PeriodicalIF":14.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141184812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advisory Board and Contents 咨询委员会和内容
IF 18.4 1区 医学 Q1 ONCOLOGY Pub Date : 2024-06-11 DOI: 10.1016/s2405-8033(24)00100-6
No Abstract
无摘要
{"title":"Advisory Board and Contents","authors":"","doi":"10.1016/s2405-8033(24)00100-6","DOIUrl":"https://doi.org/10.1016/s2405-8033(24)00100-6","url":null,"abstract":"No Abstract","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":null,"pages":null},"PeriodicalIF":18.4,"publicationDate":"2024-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141529783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Subscription & copyright page 订阅和版权页面
IF 18.4 1区 医学 Q1 ONCOLOGY Pub Date : 2024-06-11 DOI: 10.1016/s2405-8033(24)00103-1
No Abstract
无摘要
{"title":"Subscription & copyright page","authors":"","doi":"10.1016/s2405-8033(24)00103-1","DOIUrl":"https://doi.org/10.1016/s2405-8033(24)00103-1","url":null,"abstract":"No Abstract","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":null,"pages":null},"PeriodicalIF":18.4,"publicationDate":"2024-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141508834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
B7-H3: a robust target for immunotherapy in prostate cancer B7-H3:前列腺癌免疫疗法的强大靶点
IF 18.4 1区 医学 Q1 Medicine Pub Date : 2024-06-04 DOI: 10.1016/j.trecan.2024.05.003
Rafael Pulido, José I. López, Caroline E. Nunes-Xavier

B7-H3, an immune checkpoint glycoprotein, facilitates immune evasion and the promotion of tumors and is highly expressed on the surface of prostate cancer (PCa) cells, which makes it a feasible and robust candidate for immunotherapies against advanced prostate cancer. Here, we summarize and discuss recent findings on the suitability of targeting B7-H3 in PCa treatment.

B7-H3是一种免疫检查点糖蛋白,可促进免疫逃避和肿瘤的生长,并在前列腺癌(PCa)细胞表面高度表达,这使其成为针对晚期前列腺癌的免疫疗法的一个可行且稳健的候选靶点。在此,我们总结并讨论了最近关于靶向 B7-H3 治疗 PCa 的研究结果。
{"title":"B7-H3: a robust target for immunotherapy in prostate cancer","authors":"Rafael Pulido, José I. López, Caroline E. Nunes-Xavier","doi":"10.1016/j.trecan.2024.05.003","DOIUrl":"https://doi.org/10.1016/j.trecan.2024.05.003","url":null,"abstract":"<p>B7-H3, an immune checkpoint glycoprotein, facilitates immune evasion and the promotion of tumors and is highly expressed on the surface of prostate cancer (PCa) cells, which makes it a feasible and robust candidate for immunotherapies against advanced prostate cancer. Here, we summarize and discuss recent findings on the suitability of targeting B7-H3 in PCa treatment.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":null,"pages":null},"PeriodicalIF":18.4,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141258124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer 将循环肿瘤 DNA 作为可切除非小细胞肺癌的预后生物标记物
IF 18.4 1区 医学 Q1 Medicine Pub Date : 2024-06-04 DOI: 10.1016/j.trecan.2024.04.004
Chris Abbosh, Darren Hodgson, Gary J. Doherty, Davina Gale, James R.M. Black, Leora Horn, Jorge S. Reis-Filho, Charles Swanton

Systemic treatment of resectable non-small cell lung cancer (NSCLC) is evolving with emerging neoadjuvant, perioperative, and adjuvant immunotherapy approaches. Circulating tumor DNA (ctDNA) detection at clinical diagnosis, during neoadjuvant therapy, or after resection may discern high-risk patients who might benefit from therapy escalation or switch. This Review summarizes translational implications of data supporting ctDNA-based risk determination in NSCLC and outstanding questions regarding ctDNA validity/utility as a prognostic biomarker. We discuss emerging ctDNA capabilities to refine clinical tumor–node–metastasis (TNM) staging in lung adenocarcinoma, ctDNA dynamics during neoadjuvant therapy for identifying patients deriving suboptimal benefit, and postoperative molecular residual disease (MRD) detection to escalate systemic therapy. Considering differential relapse characteristics in landmark MRD-negative/MRD-positive patients, we propose how ctDNA might integrate with pathological response data for optimal postoperative risk stratification.

可切除非小细胞肺癌(NSCLC)的全身治疗正随着新辅助、围手术期和辅助免疫疗法方法的出现而不断发展。在临床诊断、新辅助治疗期间或切除术后进行循环肿瘤DNA(ctDNA)检测,可发现可能从治疗升级或转换中获益的高危患者。本综述总结了支持基于ctDNA确定NSCLC风险的数据的转化意义,以及有关ctDNA作为预后生物标记物的有效性/效用的未决问题。我们讨论了新出现的ctDNA功能,以完善肺腺癌的临床肿瘤-结节-转移(TNM)分期;新辅助治疗期间ctDNA的动态变化,以确定获得次优疗效的患者;以及术后分子残留病(MRD)检测,以升级全身治疗。考虑到地标性 MRD 阴性/MRD 阳性患者的不同复发特征,我们提出了如何将 ctDNA 与病理反应数据相结合,以优化术后风险分层。
{"title":"Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer","authors":"Chris Abbosh, Darren Hodgson, Gary J. Doherty, Davina Gale, James R.M. Black, Leora Horn, Jorge S. Reis-Filho, Charles Swanton","doi":"10.1016/j.trecan.2024.04.004","DOIUrl":"https://doi.org/10.1016/j.trecan.2024.04.004","url":null,"abstract":"<p>Systemic treatment of resectable non-small cell lung cancer (NSCLC) is evolving with emerging neoadjuvant, perioperative, and adjuvant immunotherapy approaches. Circulating tumor DNA (ctDNA) detection at clinical diagnosis, during neoadjuvant therapy, or after resection may discern high-risk patients who might benefit from therapy escalation or switch. This Review summarizes translational implications of data supporting ctDNA-based risk determination in NSCLC and outstanding questions regarding ctDNA validity/utility as a prognostic biomarker. We discuss emerging ctDNA capabilities to refine clinical tumor–node–metastasis (TNM) staging in lung adenocarcinoma, ctDNA dynamics during neoadjuvant therapy for identifying patients deriving suboptimal benefit, and postoperative molecular residual disease (MRD) detection to escalate systemic therapy. Considering differential relapse characteristics in landmark MRD-negative/MRD-positive patients, we propose how ctDNA might integrate with pathological response data for optimal postoperative risk stratification.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":null,"pages":null},"PeriodicalIF":18.4,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141258209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biosocial determinants inform on enduring cancer disparities 生物社会决定因素为癌症的持久性差异提供信息
IF 18.4 1区 医学 Q1 Medicine Pub Date : 2024-06-04 DOI: 10.1016/j.trecan.2024.05.004
David P. Turner, Robert A. Winn, Victoria J. Findlay

Social, environmental, and biological risk factors influence exposures to newly termed ‘biosocial determinants of health’. As molecular factors that lie at the intersection between lived experiences and individual biology, biosocial determinants may inform on the enduring complexity of cancer disparity across transdisciplinary studies.

社会、环境和生物风险因素影响着新近被称为 "健康的生物社会决定因素 "的暴露。生物社会决定因素是生活经历与个体生物学之间的分子因素,可为跨学科研究中癌症差异的持久复杂性提供信息。
{"title":"Biosocial determinants inform on enduring cancer disparities","authors":"David P. Turner, Robert A. Winn, Victoria J. Findlay","doi":"10.1016/j.trecan.2024.05.004","DOIUrl":"https://doi.org/10.1016/j.trecan.2024.05.004","url":null,"abstract":"<p>Social, environmental, and biological risk factors influence exposures to newly termed ‘biosocial determinants of health’. As molecular factors that lie at the intersection between lived experiences and individual biology, biosocial determinants may inform on the enduring complexity of cancer disparity across transdisciplinary studies.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":null,"pages":null},"PeriodicalIF":18.4,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141258180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Trends in cancer
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1